Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies
Mucormycosis in patients who have COVID-19 or who are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating and fatal, leading to loss of organs and emotional trauma. Radiographic manifestations are not specific, but diagnosis...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article PeerReviewed |
Language: | English English English |
Published: |
Multidisciplinary Digital Publishing Institute (MDPI)
2023
|
Subjects: | |
Online Access: | https://repository.unair.ac.id/125497/1/C-25_artikel.pdf https://repository.unair.ac.id/125497/2/Kualitas%20Karil%20C-25.pdf https://repository.unair.ac.id/125497/3/C-25_similarity.pdf https://repository.unair.ac.id/125497/ https://www.mdpi.com/2079-6382/10/9/1079 https://doi.org/10.3390/antibiotics10091079 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Airlangga |
Language: | English English English |
id |
id-langga.125497 |
---|---|
record_format |
dspace |
spelling |
id-langga.1254972023-04-29T03:52:02Z https://repository.unair.ac.id/125497/ Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies Ram Kumar Sahu, - Mounir M Salem-Bekhit, - Bedanta Bhattacharjee, - Yosif Almoshari, - Abu Md Ashif Ikbal, - Meshal Alshamrani, - Alakesh Bharali, - Ahmad Salawi, - Retno Widyowati, - Abdulrahman Alshammari, - Ibrahim Elbagory, - R Medicine RS Pharmacy and materia medica RS1-441 Pharmacy and materia medica RS200-201 Pharmaceutical dosage forms Mucormycosis in patients who have COVID-19 or who are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating and fatal, leading to loss of organs and emotional trauma. Radiographic manifestations are not specific, but diagnosis can be made through microscopic examination of materials collected from necrotic lesions. Treatment requires multidisciplinary expertise, as the fungus enters through the eyes and nose and may even reach the brain. Use of the many antifungal drugs available is limited by considerations of resistance and toxicity, but nanoparticles can overcome such limitations by reducing toxicity and increasing bioavailability. The lipid formulation of amphotericin-B (liposomal Am-B) is the first-line treatment for mucormycosis in COVID-19 patients, but its high cost and low availability have prompted a shift toward surgery, so that surgical debridement to remove all necrotic lesions remains the hallmark of effective treatment of mucormycosis in COVID-19. This review highlights the pathogenesis, clinical manifestation, and management of mucormycosis in patients who have COVID-19. Multidisciplinary Digital Publishing Institute (MDPI) 2023-02-01 Article PeerReviewed text en https://repository.unair.ac.id/125497/1/C-25_artikel.pdf text en https://repository.unair.ac.id/125497/2/Kualitas%20Karil%20C-25.pdf text en https://repository.unair.ac.id/125497/3/C-25_similarity.pdf Ram Kumar Sahu, - and Mounir M Salem-Bekhit, - and Bedanta Bhattacharjee, - and Yosif Almoshari, - and Abu Md Ashif Ikbal, - and Meshal Alshamrani, - and Alakesh Bharali, - and Ahmad Salawi, - and Retno Widyowati, - and Abdulrahman Alshammari, - and Ibrahim Elbagory, - (2023) Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics, 10 (9). pp. 1-22. ISSN 2079-6382 https://www.mdpi.com/2079-6382/10/9/1079 https://doi.org/10.3390/antibiotics10091079 |
institution |
Universitas Airlangga |
building |
Universitas Airlangga Library |
continent |
Asia |
country |
Indonesia Indonesia |
content_provider |
Universitas Airlangga Library |
collection |
UNAIR Repository |
language |
English English English |
topic |
R Medicine RS Pharmacy and materia medica RS1-441 Pharmacy and materia medica RS200-201 Pharmaceutical dosage forms |
spellingShingle |
R Medicine RS Pharmacy and materia medica RS1-441 Pharmacy and materia medica RS200-201 Pharmaceutical dosage forms Ram Kumar Sahu, - Mounir M Salem-Bekhit, - Bedanta Bhattacharjee, - Yosif Almoshari, - Abu Md Ashif Ikbal, - Meshal Alshamrani, - Alakesh Bharali, - Ahmad Salawi, - Retno Widyowati, - Abdulrahman Alshammari, - Ibrahim Elbagory, - Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
description |
Mucormycosis in patients who have COVID-19 or who are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating and fatal, leading to loss of organs and emotional trauma. Radiographic manifestations are not specific, but diagnosis can be made through microscopic examination of materials collected from necrotic lesions. Treatment requires multidisciplinary expertise, as the fungus enters through the eyes and nose and may even reach the brain. Use of the many antifungal drugs available is limited by considerations of resistance and toxicity, but nanoparticles can overcome such limitations by reducing toxicity and increasing bioavailability. The lipid formulation of amphotericin-B (liposomal Am-B) is the first-line treatment for mucormycosis in COVID-19 patients, but its high cost and low availability have prompted a shift toward surgery, so that surgical debridement to remove all necrotic lesions remains the hallmark of effective treatment of mucormycosis in COVID-19. This review highlights the pathogenesis, clinical manifestation, and management of mucormycosis in patients who have COVID-19. |
format |
Article PeerReviewed |
author |
Ram Kumar Sahu, - Mounir M Salem-Bekhit, - Bedanta Bhattacharjee, - Yosif Almoshari, - Abu Md Ashif Ikbal, - Meshal Alshamrani, - Alakesh Bharali, - Ahmad Salawi, - Retno Widyowati, - Abdulrahman Alshammari, - Ibrahim Elbagory, - |
author_facet |
Ram Kumar Sahu, - Mounir M Salem-Bekhit, - Bedanta Bhattacharjee, - Yosif Almoshari, - Abu Md Ashif Ikbal, - Meshal Alshamrani, - Alakesh Bharali, - Ahmad Salawi, - Retno Widyowati, - Abdulrahman Alshammari, - Ibrahim Elbagory, - |
author_sort |
Ram Kumar Sahu, - |
title |
Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
title_short |
Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
title_full |
Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
title_fullStr |
Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
title_full_unstemmed |
Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
title_sort |
mucormycosis in indian covid-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies |
publisher |
Multidisciplinary Digital Publishing Institute (MDPI) |
publishDate |
2023 |
url |
https://repository.unair.ac.id/125497/1/C-25_artikel.pdf https://repository.unair.ac.id/125497/2/Kualitas%20Karil%20C-25.pdf https://repository.unair.ac.id/125497/3/C-25_similarity.pdf https://repository.unair.ac.id/125497/ https://www.mdpi.com/2079-6382/10/9/1079 https://doi.org/10.3390/antibiotics10091079 |
_version_ |
1765216200541863936 |